The University of Chicago Header Logo


Olufunmilayo Olopade to Triple Negative Breast Neoplasms

This is a "connection" page, showing publications Olufunmilayo Olopade has written about Triple Negative Breast Neoplasms.
  1. Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations. Breast Cancer Res. 2023 05 25; 25(1):58.
    View in: PubMed
    Score: 0.761
  2. An enhancer variant associated with breast cancer susceptibility in Black women regulates TNFSF10 expression and antitumor immunity in triple-negative breast cancer. Hum Mol Genet. 2023 01 01; 32(1):139-150.
    View in: PubMed
    Score: 0.740
  3. Subtype-specific expression of MELK is partly due to copy number alterations in breast cancer. PLoS One. 2022; 17(6):e0268693.
    View in: PubMed
    Score: 0.714
  4. Inhibition of Copper Transport Induces Apoptosis in Triple-Negative Breast Cancer Cells and Suppresses Tumor Angiogenesis. Mol Cancer Ther. 2019 05; 18(5):873-885.
    View in: PubMed
    Score: 0.567
  5. ß-catenin regulates c-Myc and CDKN1A expression in breast cancer cells. Mol Carcinog. 2016 May; 55(5):431-9.
    View in: PubMed
    Score: 0.428
  6. Inherited predisposition to breast cancer among African American women. Breast Cancer Res Treat. 2015 Jan; 149(1):31-9.
    View in: PubMed
    Score: 0.422
  7. Triple negative breast cancer in BRCA1 mutation carriers with a complete radiologic response to neoadjuvant paclitaxel: a case report. Clin Breast Cancer. 2015 Apr; 15(2):e155-8.
    View in: PubMed
    Score: 0.418
  8. Clinicopathologic Characteristics and Prognosis of ERBB2-Low Breast Cancer Among Patients in the National Cancer Database. JAMA Oncol. 2023 04 01; 9(4):500-510.
    View in: PubMed
    Score: 0.188
  9. Response to Treatment, Racial and Ethnic Disparity, and Survival in Patients With Breast Cancer Undergoing Neoadjuvant Chemotherapy in the US. JAMA Netw Open. 2023 03 01; 6(3):e235834.
    View in: PubMed
    Score: 0.187
  10. Differences in somatic TP53 mutation type in breast tumors by race and receptor status. Breast Cancer Res Treat. 2022 Apr; 192(3):639-648.
    View in: PubMed
    Score: 0.175
  11. Profile of Pathogenic Mutations and Evaluation of Germline Genetic Testing Criteria in Consecutive Breast Cancer Patients Treated at a North Indian Tertiary Care Center. Ann Surg Oncol. 2022 Feb; 29(2):1423-1432.
    View in: PubMed
    Score: 0.170
  12. Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer. Cancer Res. 2020 02 01; 80(3):394-405.
    View in: PubMed
    Score: 0.149
  13. Adaptive Randomization of Veliparib-Carboplatin Treatment in Breast Cancer. N Engl J Med. 2016 Jul 07; 375(1):23-34.
    View in: PubMed
    Score: 0.118
  14. ß-Catenin is required for the tumorigenic behavior of triple-negative breast cancer cells. PLoS One. 2015; 10(2):e0117097.
    View in: PubMed
    Score: 0.107
  15. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis. Medicine (Baltimore). 2016 Oct; 95(40):e4975.
    View in: PubMed
    Score: 0.030
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.